Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tasly Pharmaceuticals has awarded its global Phase III T89 trial to ICON, a provider of outsourced development services to the pharmaceutical and biotechnology industry.
Subscribe to our email newsletter
T89, also known as Dantonic pill, is a botanical product used to treat chronic stable angina pectoris due to coronary heart disease and aims to become the first traditional Chinese medicine to receive FDA approval in the US.
Tasly Pharmaceuticals is conducting two global Phase III trials for the Dantonic pill and ICON has received the 3-arm Phase III clinical trial.
Tasly Pharmaceuticals president Henry Sun said they looked for a company with large global infrastructure supported by advanced regional testing facilities for the Phase III trials.
"In ICON we have found a trusted development partner with all of these attributes and one that also has a strong reputation for delivering quality clinical programs," Sun added.